Anna Fridman-Dror

Title: The Innovative Contributions of Anna Fridman-Dror

Introduction

Anna Fridman-Dror is a prominent inventor based in Kibbutz Dalia, Israel. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies for cancer treatment. With a total of 5 patents to her name, her work is paving the way for new therapeutic approaches in oncology.

Latest Patents

Fridman-Dror's latest patents include groundbreaking methods for the use of anti-ILT2 antibodies. The first patent details monoclonal antibodies or antigen-binding portions against ILT2, along with pharmaceutical compositions and methods for producing them. This invention also outlines methods for treating cancer by administering these antibodies or compositions. The second patent focuses on the provision of monoclonal anti-ILT2 antibodies and their use in cancer treatment, including methods for patient selection.

Career Highlights

Throughout her career, Anna Fridman-Dror has worked with notable companies such as Biond Biologics Ltd. and Biond Biologies Ltd. Her innovative research has positioned her as a key figure in the biotechnology sector, contributing to advancements in cancer therapies.

Collaborations

Some of her notable coworkers include Tsuri Peretz and Dana Haves Ziv, who have collaborated with her on various projects in the field of biotechnology.

Conclusion

Anna Fridman-Dror's contributions to the field of biotechnology, particularly in cancer treatment, highlight her role as an influential inventor. Her patents and collaborations reflect her commitment to advancing medical science and improving patient outcomes.